Sage Therapeutics Inc Reports Results For The Quarter Ended December 31: Earnings Summary

Sage Therapeutics

11/02/2025 22:01

* SAGE Therapeutics Inc  SAGE.OQ  reported a quarterly
adjusted
loss of $1.56​​ per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of $-1.80.  The mean expectation of
seventeen analysts for the quarter was for a loss of $1.51 per
share. Wall Street expected results to range from $-2.44 to -99
cents per share.
    * Revenue fell 83.6% to $12.82 million from a year ago;
analysts
expected $14.44 million. 
    * SAGE Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.56​.
    * The company reported a quarterly loss of $95.78 million.
    * SAGE Therapeutics Inc shares had risen by 33.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.2%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 15
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for SAGE Therapeutics
Inc is $8.83 
This summary was machine generated from LSEG data February 11 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -1.51          -1.56          Missed
 Sep. 30 2024      -1.53          -1.53          Met
 Jun. 30 2024      -1.66          -1.70          Missed
 Mar. 31 2024      -1.65          -1.80          Missed